Capital Fund Management (CFM)
NVAX icon

Capital Fund Management (CFM)’s Novavax NVAX Stock Holding History

Capital Fund Management (CFM)’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-287,804
Closed -$2.38M – 2239
2024
Q4 		$2.31M Sell
287,804
-64,469
-18% -$622K 0.01% 1428
2024
Q3 		$4.45M Buy
+352,273
New +$4.55M 0.01% 1078
2023
Q1 		– Sell
-518,075
Closed -$4.77M – 1688
2022
Q4 		$5.33M Buy
518,075
+226,379
+78% +$4M 0.04% 598
2022
Q3 		$5.31M Buy
291,696
+82,024
+39% +$3.55M 0.04% 525
2022
Q2 		$10.8M Buy
209,672
+148,740
+244% +$7.7M 0.1% 292
2022
Q1 		$4.49M Buy
+60,932
New +$5.43M 0.04% 612
2021
Q3 		– Sell
-62,286
Closed -$13.7M – 1705
2021
Q2 		$13.2M Buy
+62,286
New +$11.4M 0.1% 248
2016
Q1 		– Sell
-657
Closed -$110K – 1751
2015
Q4 		$110K Buy
+657
New +$101K ﹤0.01% 1486

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Fund Management (CFM)'s NVAX Position: Q1 2025 in Review

Capital Fund Management (CFM) sold out of Novavax (NVAX) in Q1 2025, closing a stake of 287,804 shares — an estimated $2.38M sold.

Capital Fund Management (CFM) first reported a position in NVAX in Q4 2015 and held it in 8 quarters. The position peaked at $13.2M in Q2 2021. 245 funds tracked by Wall St. Rank hold NVAX as of Q1 2025.

  • Capital Fund Management (CFM) reported no remaining Novavax position as of Q1 2025 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 287,804 Novavax shares in Q1 2025, an estimated $2.38M.
  • Capital Fund Management (CFM) first reported a position in Novavax in Q4 2015 and held it in 8 quarters.
  • Capital Fund Management (CFM)'s Novavax position peaked at $13.2M in Q2 2021.
  • 245 funds tracked by Wall St. Rank held Novavax as of Q1 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2025, filed 14 May 2025.